Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sBOM:544742 +5.09%14 EBITDA Margin % is 11.48% as of Sep. 2025, which is 41% below its 10-year median of 19.39. GuruFocus rates BOM:544742 with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 959 Drug Manufacturers companies, Sai Parenteral's ranks worse than 51.82% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sai Parenteral's's EBITDA for the
six
months ended in Sep. 2025 was ₹347 Mil. Sai Parenteral's's Revenue for the
six
months ended in Sep. 2025 was ₹3,025 Mil. Therefore, Sai Parenteral's's EBITDA margin for the quarter that ended in Sep. 2025 was 11.48%.
Sai Parenteral's (BOM:544742) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sai Parenteral's EBITDA Margin % Related Terms
Sai Parenteral's EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's EBITDA Margin % Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
EBITDA Margin %
19.39
21.53
10.98
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
EBITDA Margin %
0.00
0.00
0.00
11.48
BOM:544742 vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's (BOM:544742) has a EBITDA Margin % of 11.48% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sai Parenteral's and its competitors. This is 41% below median its historical median of 19.39. Over the past decade, Sai Parenteral's' EBITDA Margin % has ranged from 10.98 to 21.53. According to the industry distribution chart, Sai Parenteral's ranks #497 out of 959 companies in the Drug Manufacturers industry, placing it in the top 51.8%.
Is Sai Parenteral's' EBITDA Margin % too high?
Sai Parenteral's' current EBITDA Margin % of 11.48% is 41% below median its 10-year median of 19.39. Over the past 10 years, this metric has ranged from a low of 10.98 to a high of 21.53. The Drug Manufacturers industry median EBITDA Margin % is 12.11. Sai Parenteral's' value of 11.48% is 5.2% below this industry median. Based on the distribution chart, Sai Parenteral's ranks #497 out of 959 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #497 out of 959 companies for EBITDA Margin %. This places Sai Parenteral's in the lower half of its industry. The industry median EBITDA Margin % is 12.11. Sai Parenteral's' value of 11.48% is 5.2% below this benchmark. Historically, Sai Parenteral's' own EBITDA Margin % has ranged from 10.98 to 21.53 over the past decade. While the company's 10-year median is 19.39 vs. the industry median of 12.11, Sai Parenteral's has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.11, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Parenteral's's current EBITDA Margin % of 11.48% is 5.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current EBITDA Margin % is 11.48%, which is 41% below median its own 10-year median of 19.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (BOM:544742) has a current EBITDA Margin % of 11.48%. The current EBITDA Margin % is 11.48%, which is 41% below median its 10-year median of 19.39 and 5.2% below the Drug Manufacturers industry median of 12.11. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sai Parenteral's (BOM:544742), the current EBITDA Margin % is 11.48% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for BOM:544742
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544742 has been successfully added to your 
